Zhang et al. proposed the DLBCL risk rating model based on analyzing 16 lipid metabolism-related markers (ACSM3, ARSK, CEPT1, DGKE, EHHADH, ENPP7, FABP4, FASN, LPGAT1, MECR, PTDSS2, RAN, ARSJ, CYP27A1, FAM120B, and PIK3CG), which can compensate for the limitations of the IPI scoring system [7]. The gene discussed is CYP27A1; the disease is diffuse large B-cell lymphoma.